FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216015655> ?p ?o ?g. }

• W3216015655 abstract "Implanted vagus nerve stimulation (VNS) delivered concurrently with upper limb rehabilitation has been shown to improve arm function after stroke. Transcutaneous auricular VNS (taVNS) offers a non-invasive alternative to implanted VNS and may provide similar therapeutic benefit. There is much discussion about the optimal approach for combining VNS and physical therapy, as such we sought to determine whether taVNS administered during robotic training, specifically delivered during the premotor planning stage for arm extension movements, would confer additional motor improvement in patients with chronic stroke. Thirty-six patients with chronic, moderate-severe upper limb hemiparesis (>6 months; mean Upper Extremity Fugl-Meyer score = 25 ± 2, range 13-48), were randomized to receive 9 sessions (1 h in length, 3x/week for 3 weeks) of active (N = 18) or sham (N = 18) taVNS (500 ms bursts, frequency 30 Hz, pulse width 0.3 ms, max intensity 5 mA, ∼250 stimulated movements per session) delivered during robotic training. taVNS was triggered by the onset of a visual cue prior to center-out arm extension movements. Clinical assessments and surface electromyography (sEMG) measures of the biceps and triceps brachii were collected during separate test sessions. Significant motor improvements were measured for both the active and sham taVNS groups, and these improvements were robust at 3 month follow-up. Compared to the sham group, the active taVNS group showed a significant reduction in spasticity of the wrist and hand at discharge (Modified Tardieu Scale; taVNS = -8.94% vs. sham = + 2.97%, p < 0.05). The EMG results also demonstrated significantly increased variance for the bicep peak sEMG amplitude during extension for the active taVNS group compared to the sham group at discharge (active = 26.29% MVC ± 3.89, sham = 10.63% MVC ± 3.10, mean absolute change admission to discharge, p < 0.01), and at 3-month follow-up, the bicep peak sEMG amplitude was significantly reduced in the active taVNS group (P < 0.05). Thus, robot training improved the motor capacity of both groups, and taVNS, decreased spasticity. taVNS administered during premotor planning of movement may play a role in improving coordinated activation of the agonist-antagonist upper arm muscle groups by mitigating spasticity and increasing motor control following stroke. Clinical Trial Registration: www.ClinicalTrials.gov, identifier (NCT03592745)." @default.
• W3216015655 created "2021-12-06" @default.
• W3216015655 creator A5002419756 @default.
• W3216015655 creator A5009247068 @default.
• W3216015655 creator A5016254801 @default.
• W3216015655 creator A5023575503 @default.
• W3216015655 creator A5033029548 @default.
• W3216015655 creator A5057361115 @default.
• W3216015655 creator A5060573107 @default.
• W3216015655 creator A5069290982 @default.
• W3216015655 creator A5072707807 @default.
• W3216015655 date "2021-11-25" @default.
• W3216015655 modified "2023-10-14" @default.
• W3216015655 title "Transcutaneous Auricular Vagus Nerve Stimulation (tAVNS) Delivered During Upper Limb Interactive Robotic Training Demonstrates Novel Antagonist Control for Reaching Movements Following Stroke" @default.
• W3216015655 cites W1599114047 @default.
• W3216015655 cites W1974357213 @default.
• W3216015655 cites W1978441796 @default.
• W3216015655 cites W1995855357 @default.
• W3216015655 cites W2000749160 @default.
• W3216015655 cites W2009066073 @default.
• W3216015655 cites W2012834211 @default.
• W3216015655 cites W2021713984 @default.
• W3216015655 cites W2025995993 @default.
• W3216015655 cites W2026950175 @default.
• W3216015655 cites W2036085592 @default.
• W3216015655 cites W2055942912 @default.
• W3216015655 cites W2059694151 @default.
• W3216015655 cites W2079610925 @default.
• W3216015655 cites W2093100489 @default.
• W3216015655 cites W2098661447 @default.
• W3216015655 cites W2100975989 @default.
• W3216015655 cites W2105301020 @default.
• W3216015655 cites W2106280308 @default.
• W3216015655 cites W2117597191 @default.
• W3216015655 cites W2119985669 @default.
• W3216015655 cites W2122048922 @default.
• W3216015655 cites W2128795534 @default.
• W3216015655 cites W2136447622 @default.
• W3216015655 cites W2137456982 @default.
• W3216015655 cites W2140253770 @default.
• W3216015655 cites W2157221077 @default.
• W3216015655 cites W2163682792 @default.
• W3216015655 cites W2164072590 @default.
• W3216015655 cites W2165018198 @default.
• W3216015655 cites W2166044895 @default.
• W3216015655 cites W2205637517 @default.
• W3216015655 cites W2231595046 @default.
• W3216015655 cites W2346795597 @default.
• W3216015655 cites W2611988632 @default.
• W3216015655 cites W2613644109 @default.
• W3216015655 cites W2772182345 @default.
• W3216015655 cites W2776458751 @default.
• W3216015655 cites W2883279567 @default.
• W3216015655 cites W2892513127 @default.
• W3216015655 cites W2926545412 @default.
• W3216015655 cites W2951239678 @default.
• W3216015655 cites W2962982115 @default.
• W3216015655 cites W3005970032 @default.
• W3216015655 cites W3013157611 @default.
• W3216015655 cites W3153909772 @default.
• W3216015655 doi "https://doi.org/10.3389/fnins.2021.767302" @default.
• W3216015655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34899170" @default.
• W3216015655 hasPublicationYear "2021" @default.
• W3216015655 type Work @default.
• W3216015655 sameAs 3216015655 @default.
• W3216015655 citedByCount "16" @default.
• W3216015655 countsByYear W32160156552022 @default.
• W3216015655 countsByYear W32160156552023 @default.
• W3216015655 crossrefType "journal-article" @default.
• W3216015655 hasAuthorship W3216015655A5002419756 @default.
• W3216015655 hasAuthorship W3216015655A5009247068 @default.
• W3216015655 hasAuthorship W3216015655A5016254801 @default.
• W3216015655 hasAuthorship W3216015655A5023575503 @default.
• W3216015655 hasAuthorship W3216015655A5033029548 @default.
• W3216015655 hasAuthorship W3216015655A5057361115 @default.
• W3216015655 hasAuthorship W3216015655A5060573107 @default.
• W3216015655 hasAuthorship W3216015655A5069290982 @default.
• W3216015655 hasAuthorship W3216015655A5072707807 @default.
• W3216015655 hasBestOaLocation W32160156551 @default.
• W3216015655 hasConcept C126322002 @default.
• W3216015655 hasConcept C127413603 @default.
• W3216015655 hasConcept C141071460 @default.
• W3216015655 hasConcept C1862650 @default.
• W3216015655 hasConcept C24998067 @default.
• W3216015655 hasConcept C2776882386 @default.
• W3216015655 hasConcept C2777515770 @default.
• W3216015655 hasConcept C2778216619 @default.
• W3216015655 hasConcept C2780087125 @default.
• W3216015655 hasConcept C2780645631 @default.
• W3216015655 hasConcept C2781156865 @default.
• W3216015655 hasConcept C2781404750 @default.
• W3216015655 hasConcept C2781425419 @default.
• W3216015655 hasConcept C42219234 @default.
• W3216015655 hasConcept C71924100 @default.
• W3216015655 hasConcept C78519656 @default.
• W3216015655 hasConcept C99508421 @default.
• W3216015655 hasConceptScore W3216015655C126322002 @default.
• W3216015655 hasConceptScore W3216015655C127413603 @default.
• W3216015655 hasConceptScore W3216015655C141071460 @default.
• W3216015655 hasConceptScore W3216015655C1862650 @default.

• next